| 8.46 -0.39 (-4.41%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.03 | 1-year : | 12.89 |
| Resists | First : | 9.44 | Second : | 11.03 |
| Pivot price | 8.07  |
|||
| Supports | First : | 7.55 |
Second : | 6.38 |
| MAs | MA(5) : | 8.56 |
MA(20) : | 7.96 |
| MA(100) : | 6.58 |
MA(250) : | 7.46 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 73.8 |
D(3) : | 78.1 |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 11.52 | Low : | 5.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NVCT ] has closed below upper band by 28.8%. Bollinger Bands are 74% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.93 - 8.98 | 8.98 - 9.02 |
| Low: | 8.17 - 8.22 | 8.22 - 8.27 |
| Close: | 8.38 - 8.46 | 8.46 - 8.54 |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Fri, 09 Jan 2026
We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth - simplywall.st
Wed, 17 Dec 2025
Nuvectis Pharma Announces the Initiation of the Phase 1b - GlobeNewswire
Mon, 15 Dec 2025
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 40 (%) |
| Held by Institutions | 15.6 (%) |
| Shares Short | 1,430 (K) |
| Shares Short P.Month | 1,330 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -62.5 % |
| Return on Equity (ttm) | -145 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -6.18 |
| PEG Ratio | 0 |
| Price to Book value | 9 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|